HER2- and EGFR-positive breast cancer cells resistant to lapatinib, a tyrosine kinase inhibitor that blocks the activation of the EGFR and HER2 pathways, revealed increased activity of HPSE. This evidence concerns the gene EGFR and breast carcinoma.